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Metabolic effects 
of antihyperglycemic agents 
and mortality: meta‑analysis 
of randomized controlled trials
Dimitris Varvaki Rados1*, Camila Viecceli1, Lana catani pinto1, fernando Gerchman1,2, 
Cristiane Bauermann Leitão1,2 & Jorge Luiz Gross1,2,3
The effects of antihyperglycemic medications on cardiovascular events and mortality are 
heterogeneous and their effects on intermediate factors might explain these differences. This 
systematic review explores the relationship between metabolic factors, mechanism of action, and 
mortality effects of antihyperglycemic medications in type 2 diabetes. Randomized trials assessing the 
effects of antihyperglycemic medications on all‑cause or cardiovascular mortality in type 2 diabetes 
were included. Myocardial infarction, stroke, and heart failure were secondary outcomes. The effects 
of medications on HbA1c, severe hypoglycemia (SH), body weight, systolic blood pressure (SBP), and 
mechanism of action were evaluated. Meta‑analyses and meta‑regressions were performed grouping 
studies according to the above‑cited factors. All‑cause mortality was lower for medications that 
reduced HbA1c, SH, body weight, and SBP. Decreased cardiovascular mortality was associated with 
lower HbA1c, SH, SBP. Myocardial infarction and stroke were also associated with favorable metabolic 
profile. These findings were not confirmed in meta‑regression models. Medications associated with 
lower SH, body weight and SBP had a lower risk of heart failure. In conclusion, medications with 
better metabolic profile were associated with reduced all‑cause and cardiovascular mortality. These 
findings are based on indirect comparisons and must be applied cautiously.
Subjects with type 2 diabetes have a high risk of cardiovascular disease, which is the leading cause of death and 
disability. Many factors influence this risk, such as glucose control, hypoglycemia frequency, body weight, and 
blood  pressure1–3.
Unexpectedly, studies analyzing the role of intensified glucose control on cardiovascular mortality were 
able to achieve significant differences in glycemic control but did not find a reduction in  events4–6. This lack of 
benefit may be attributable to the increased number of hypoglycemic events and weight gain associated with 
strict glycemic  control4–6.
Several classes of antihyperglycemic medications have been approved for the treatment of type 2 diabetes, 
but, until recently, metformin was the only medication proven to reduce cardiovascular events and mortality in 
patients with this  condition7. In the last years, cardiovascular safety trials showed that some sodium-glucose-
linked cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are also 
capable of reducing cardiovascular events and all-cause mortality in high-risk  populations8–11. Although these 
medications have different mechanisms of action and effects on glucose values, they share similar favorable 
metabolic effects, such as weight loss, and reduced risk of  hypoglycemia12. Furthermore, the mechanism of action 
may not be the only determinant of the effects of a medication on cardiac events, as different representatives of 
the same class seem to have diverse effects on cardiovascular  events8,11,13,14.
Joint guideline from the European Association for the Study of Diabetes and American Diabetes Association 
recommend a patient-centered  approach15. This is based on the selection of medications in type 2 diabetes based 
on patient factors and considering the heterogeneity of treatment options, such as weight effects, hypoglycemia 
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risk, and previous cardiovascular  events15. Also, medications are classified as pharmacological classes, and not 
according to individual representatives or their effects on the above  factors15. Whether this approach leads to 
better outcomes to patients is unknown and is mainly based on expert’s opinion.
Considering the heterogeneity between antihyperglycemic agents, we hypothesized that antihyperglycemic 
medications that lead to better glycemic control, lower severe hypoglycemia risk, lower body weight, and lower 
blood pressure might reduce the risk of death (all-cause or cardiovascular). We also explored if these outcomes 
are influenced by the mechanism of action of the medications. The objective of this systematic review with 
meta-analysis is to evaluate the relationship between the above factors, the treatment with antihyperglycemic 
medications in type 2 diabetic subjects, and mortality and cardiovascular events.
Methods
We registered this review and meta-analysis in the International Prospective Register of Systematic Reviews 
(PROSPERO) under number CRD42016043895. This report follows the PRISMA statement for systematic 
 reviews16. Ethical approval was exempted.
Eligibility, data sources, and searches. Studies were eligible if were performed in subjects with type 2 
diabetes (patients), evaluated any antihyperglycemic medication (intervention), reported all-cause or cardiovas-
cular mortality (outcome) and were randomized controlled parallel trials (study); no specific comparator was 
defined. We searched PubMed, EMBASE, the Cochrane Library, and clinicaltrials.org from inception up to May 
2020 for randomized controlled trials, performed in patients with type 2 diabetes, that reported any of the main 
outcomes (all-cause or cardiovascular mortality). There was no additional restriction on the searches. The search 
terms were type 2 diabetes AND mortality OR cardiovascular mortality AND randomized controlled trial. A hand 
search of reference lists of previous systematic reviews and key articles was also performed, and all potentially 
eligible studies were considered for review.
Study selection. Two investigators (DVR and CV) independently screened potentially relevant studies 
based on titles and abstracts. Studies that met inclusion criteria were thoroughly reviewed. Consensus resolved 
disagreements. Articles were included if they were randomized controlled trials, included antihyperglycemic 
medications approved for the treatment of type 2 diabetes, had lasted more than one year and reported at least 
one of the outcomes of interest (all-cause or cardiovascular mortality).
Data extraction. Two investigators (DVR and CV) independently extracted relevant data from studies. 
Change in glycated hemoglobin (HbA1c), body weight, systolic blood pressure, and severe hypoglycemia events, 
were also extracted. We evaluated all-cause mortality and cardiovascular mortality as primary outcomes and 
the incidence of cardiovascular events (acute myocardial infarction, stroke, and heart failure) as secondary out-
comes. As recommended, when the study comprised more than two groups, we either (a) spliced the interven-
tion group to compare with each of the control groups; or (b) combined the control groups to compare with 
the intervention group, to perform pair-wise  comparisons17. Discrepancies in extracted data were resolved by 
consensus.
Quality assessment. The Cochrane Collaboration tool was used to assess the bias risk of individual 
 studies18. Using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) 
method, we ranked the quality of the evidence of each outcome as high, moderate, low, or very  low17. Summary 
of findings table was constructed using GRADEPRO  software19.
Data synthesis and analysis. To analyze the effects of the factors (glycemic control, severe hypoglycemia 
risk, body weight, and blood pressure changes) on the outcomes of interest, we adopted the following approach. 
First, we extracted each variable numerical change from baseline to end of follow-up in the experimental arm. 
Second, we also extracted the differences between study arms (variable delta of the intervention group minus 
variable delta of the control group). At last, the effects of an experimental intervention in the factor was classified 
as “reduction” of the factor (HbA1c, body weight or blood pressure) or “no reduction”. The variable was classified 
as “reduction” if both changes (variation during follow-up in the experimental arm and between experimental 
and control arms) were equal or greater than: (a) 0.3% for HbA1c; (b) 1 kg for body weight or; (c) 1 mmHg for 
systolic blood pressure. We opted this approach as it allows to select interventions that showed real improve-
ments in glycemic control, body weight, or systolic blood pressure, and not a deterioration in the experimental 
arm that was only smaller than the observed in control group. For example, in UKPDS33 patients in the sulfo-
nylurea group had a mean body weight gain of 2.15 kg, and in the insulin group patients gained 4  kg20. With this 
approach, we avoided classifying this difference as “weigh reduction”. For severe hypoglycemia, the absolute risk 
difference between intervention and control arms was used. These categories (“reduction” and “no reduction”) 
were used to stratify the meta-analyses. As an additional and exploratory analysis, we evaluated if the mecha-
nism of action would influence the results and medications were classified as: (a) insulin / secretagogues; (b) 
insulin-sensitizing; (c) incretins and; (d) SGLT2i.
The outcomes were combined with Mantel–Haenszel relative risks (RR) with random-effects  model17. We 
evaluated statistical heterogeneity with Cochran’s Q and the  I2 test (P < 0.1 and  I2 > 50% indicated elevated het-
erogeneity, respectively). Small study bias was assessed with the funnel plot asymmetry and with the Begg and 
Egger tests; if bias was identified, we performed a trim-and-fill computation to evaluate the potential effect 
of unpublished studies on the  results21,22. Our objective involved the evaluation and comparison of subgroup 
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analyses in meta-analysis. We followed Cochrane Handbook recommendations for comparing subgroups in 
random effects model, besides performing stratified analyses, we also compared the subgroups (factors and 
mechanisms of action) with metaregressions using dichotomous  variables17,23. Analyses were performed using 
Stata 13.0 software (StataCorp, College Station, USA). Graphics were constructed with forestplot package using 
Rstudio program.
Results
Database review and characteristics of selected studies. Electronic and manual searches retrieved 
2,180 potential studies, of which 2077 were excluded based on titles and abstracts and 103 were selected for full-
text review. In total, 46 studies met the inclusion criteria. A complete flow diagram of study inclusion is shown 
in Fig. 1.
The included studies represent a total of 216,575 patients and a total of 15,304 all-cause deaths and 8,994 
cardiovascular deaths. Summarized study characteristics are presented in Table 1; detailed characteristics of 
the included studies are presented in Table S1 and S2 (Supplementary material). Studies evaluated the effects of 
almost every class of antihyperglycemic agents; incretin-based therapies were the most common medications 
assessed (thirteen studies of dipeptidyl peptidase-4 inhibitors and eight studies of GLP-1RA). About half of the 
studies (24 from 46) had active comparators, of which sulfonylurea was the predominant class.
Three studies had more than two arms and needed group splicing or combining to be included in this meta-
analysis. In the ADOPT and PIONEER 4  studies24,25, we spliced one study arm (ADOPT: metformin; PIONEER 
4: placebo) and compared it to remainder arms. In the 4-T  study26, we combined the groups receiving bolus 
insulin (prandial insulin and biphasic insulin).
Figure 1.  Studies flowchart.
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53 N.A 1,293 No reduction Reduction No reduction N.A 10.7
Turner20 1998 Intensive with sulfonylurea
Intensive with 
insulin 54 N.A 2,145 No reduction N.A No reduction N.A 10
Dormandy41 2005 Pioglitazone 61.9 100% 5,238 Reduction No reduction No reduction N.A 2.8
Kahn24 2006 Metformin Rosiglitazone 57.9 N.A 2,183 No reduction No reduction Reduction N.A 4
Kahn24 2006 Metformin Glibencla-mide 57.9 N.A 2,168 No reduction Reduction Reduction N.A 4
Mazzone42 2006 Pioglitazone Glimepiride 59.3 N.A 458 Reduction Reduction No reduction No reduction 1.5
Nauck43 2006 Sitagliptin Glipizide 56.8 N.A 1,172 No reduction Reduction Reduction N.A 1
Dargie44 2007 Rosiglitazone 64.3 N.A 224 Reduction N.A No reduction N.A 1
Chan45 2008 Sitagliptin Glipizide 68.9 44% 91 No reduction Reduction No reduction N.A 4.5




66 32% 11,140 N.A No reduction N.A N.A 5
Holman26 2009 Basal-bolus or bolus only Basal only 61.7 N.A 708 No reduction No reduction No reduction No reduction 3
Home46 2009 Rosiglitazone Metformin or Sulfonylureia 58.4 32% 4,447 No reduction No reduction No reduction No reduction 5.5
Kooy47 2009 Metformin 64 N.A 390 No reduction N.A No reduction Reduction 4.3
Bertrand48 2010 Rosiglitazone 64.2 N.A 193 Reduction N.A No reduction No reduction 1
Gaziano49 2010 Bromocriptin QR 59.5 37% 3,070 No reduction N.A No reduction Reduction 1
Giles50 2010 Pioglitazone Glibencla-mide 64 N.A 300 No reduction N.A No reduction No reduction 1
Matthews51 2010 Vildagliptin Glimepiride 57.5 N.A 3,118 No reduction N.A No reduction N.A 2
Gallwitz52 2012 Exenatide Glimepiride 56 N.A 977 No reduction No reduction Reduction Reduction 3
Gallwitz53 2012 Linagliptin Glimepiride 59.8 N.A 1551 No reduction Reduction Reduction N.A 2
Garber54 2012 Degludec Glargine 59.2 N.A 992 No reduction No reduction No reduction N.A 1
Gerstein55 2012 Glargine Control 64.5 59% 12,537 No reduction No reduction No reduction No reduction 6.2
Zinman56 2012 Degludec Glargine 59.3 N.A 1,030 No reduction Reduction No reduction N.A 1
Cefalu57 2013 Canagliflozin Glimepiride 56.1 N.A 1,450 No reduction Reduction Reduction Reduction 1
Hong58 2013 Metformin Glipizide 62.8 100% 304 No reduction N.A Reduction Reduction 3
Scirica59 2013 Saxagliptin 65.1 79% 16,492 No reduction No reduction No reduction N.A 2.1
White60 2013 Alogliptin 61 100% 5,380 Reduction No reduction No reduction N.A 1.5
Ridder-
strale61 2014 Empagliflozin Glimepiride 56.2 N.A 1545 No reduction N.A Reduction Reduction 2
Blonde62 2015 Dulaglutide Glargine 59.1 N.A 884 No reduction Reduction No reduction No reduction 1
Giorgino63 2015 Dulaglutide Glargine 56.5 N.A 807 No reduction Reduction Reduction No reduction 1.5
Green64 2015 Sitagliptin 65.4 74% 14,671 N.A No reduction N.A N.A 3
Pfeffer13 2015 Lixisenatide 59.9 100% 6,068 Reduction Reduction No reduction No reduction 2.1
Zinman9 2015 Empagliflozin 63.1 100% 7,020 Reduction Reduction No reduction No reduction 3.1
Marso11 2016 Semaglutide 64.6 N.A 9,340 Reduction Reduction Reduction Reduction 3.8
Marso8 2016 Liraglutide 64.2 100% 3,297 Reduction N.A Reduction Reduction 2
Holman65 2017 Exenatide 62 73% 14,752 Reduction No reduction No reduction Reduction 3.2
Marso66 2017 Degludec Glargine 64.9 63% 7,637 No reduction Reduction No reduction No reduction 1.99
Neal10 2017 Canagliflozin 63.2 66% 10,142 Reduction N.A Reduction Reduction 3.6
Vaccaro67 2017 Pioglitazone Glimepiride 62.4 11% 3,028 No reduction Reduction No reduction No reduction 4.7
Hernndez68 2018 Albiglutide 64.15 100% 9,463 Reduction Reduction No reduction No reduction 1.6
Rosenstock69 2018 Linagliptin 65.85 59% 6,979 N.A Reduction No reduction No reduction 2.2
Gerstein70 2019 Dulaglutide 66.2 31% 9,901 Reduction Reduction Reduction Reduction 5.4
Husain71 2019 Oral Semaglu-tide 66 85% 3,183 Reduction No reduction Reduction Reduction 1.3
Perkovic72 2019 Canagliflozin 63.05 50% 4,401 No reduction N.A No reduction Reduction 2.62
Pieber73 2019 Oral Semaglu-tide Sitagliptin 57.9 N.A 504 Reduction No reduction Reduction N.A 1
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Overall, the risk of bias was low, especially for randomization and blinding. For incomplete outcome data, 
six studies had high risk of bias (mostly due to an unbalanced number of patients without follow-up informa-
tion). Detailed assessment information on the risk of bias of individual studies is presented in the supplementary 
appendix (Table S3, Supplementary material).
Main results. As shown in Fig. 2 and Table S4 (Supplementary material), antihyperglycemic medications are 
associated with reduced risk of all-cause and cardiovascular mortality overall. Stratifying the analysis accord-
ing to glycemic control, severe hypoglycemia risk, body weight, and systolic blood pressure showed that treat-
ments that lead to reduction of these factors (except weight change for cardiovascular mortality) were associated 
with lower all-cause mortality. Glycemic control was the factor with the greatest numeric reduction of all-cause 
mortality (RR 0.90 [95% CI 0.84–0.96]) and cardiovascular mortality (RR 0.88 [95% CI 0.80–0.96]); Table S3, 


























Pratley25 2019 Liraglutide 56 N.A 355 Reduction Reduction Reduction Reduction 1
Wiviott74 2019 Dapagliflozin 63.95 41% 17,160 Reduction Reduction Reduction Reduction 4.2
Rosenstock75 2019 Linagliptin Glimepiride 64.1 34% 6,033 No reduction Reduction Reduction No reduction 6.3
Table 1.  Studies characteristics. N.A. = not available; CV = cardiovascular.
Figure 2.  Forest plot for antihyperglycemic agents and all-cause and cardiovascular mortality relative risks 
according to glycemic control, severe hypoglycemia risk, weight variation, and systolic blood pressure variation. 
Legend: (A) all-cause mortality; (B) cardiovascular mortality.
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Regarding analyses evaluating mechanisms of action of medications (Table S4 and Figure S1A and S1B, 
Supplementary material), only incretins were associated with reduced all-cause or cardiovascular mortality. 
Meta-regression models found that this difference was not statistically significant.
Statistical heterogeneity was low (Table S4, Supplementary material). Small study bias was not identified with 
Egger and Begg tests and funnel plot inspection (Supplementary material, Figure S2 A and B).
Secondary outcomes. Treatments that lead to lower HbA1c, severe hypoglycemia risk, body weight, and 
systolic blood pressure were associated with a lower risk for myocardial infarction (Table S4 and Figures S1C 
and S1D, Supplementary material). Meta-regressions did not confirm these findings. Statistical heterogeneity 
was low. Small study bias risk was detected for myocardial infarction (Figure S2C, Supplementary material), but 
trim and fill computation did not change the results.
Reduction of HbA1c, body weight, and systolic blood pressure was associated with lower stroke risk (Table S4 
and Figures S1E and S1F, Supplementary material). Meta-regression analyses also did not confirm these findings. 
Statistical heterogeneity was low, and small study bias was not identified (Figure S2D, Supplementary material). 
Insulin sensitizers and incretins were associated with lower stroke risk. Although meta-regression did not confirm 
these associations, for insulin sensitizers the results were borderline (P = 0.055).
As shown in Table S4 and Figures S1G and S1H (Supplementary material), reduction of severe hypoglycemia 
risk, body weight, and systolic blood pressure factors were associated with a lower risk of heart failure. None of 
this factors were confirmed in meta-regression. Of note, statistical heterogeneity was elevated in heart failure 
analyses. Small study bias was not identified (Figure S2E, Supplementary material). Regarding mechanism of 
action, insulin sensitizers were associated with a higher risk of heart failure and SGLT2i were associated with 
lower risk, both in stratified and meta-regression analyses.
Grading quality of evidence. The GRADE quality of evidence for all outcomes was moderate and the 
summary of findings are presented in supplementary material (Table S5, Supplementary material). Despite being 
based on high-quality studies with low risk of bias, our observations on the effects of clinical factors on the out-
comes of interest (all-cause and cardiovascular mortality, myocardial infarction, stroke, and heart failure) are 
indirect due to the nature of the  analysis17.
Discussion
Based on data from high-quality RCTs, we found that antihyperglycemic agents that lead to lower HbA1c, severe 
hypoglycemia risk, body weight, and systolic blood pressure were associated with reduced risk of all-cause and 
myocardial infarction in patients with type 2 diabetes. Cardiovascular mortality was associated with the same 
factors except body weight. As the analyses are indirect, based on aggregated patient data and meta-regression 
models did not confirm the findings, this information must be applied and generalized cautiously.
The results for secondary outcomes are also interesting. The association of SGLT2i with reduced risk for heart 
failure and insulin sensitizers with a higher risk for heart failure has been already  shown27. However, the relation 
between severe hypoglycemia and heart failure is novel. The mechanism may be a true effect of hypoglycemia 
on myocardial  cells28, however it is more likely to represent medications with safer cardiovascular profile. The 
association between insulin sensitizers and stroke has been observed  previously7,29. Lower insulin resistance may 
be the promoter of this benefit, and numerically has a greater effect on stroke than myocardial infarction  risk30.
These findings are based on an extensive and systematic literature review. The studies identified had mostly 
low risk of bias. This allowed us to explore our objective with high quality data and with a large number of 
patients. The definition of “reduction” of a metabolic factor combined the differences within and between arms to 
improve confidence in the classification. We also followed the recommended statistical approach to compare the 
subgroups of medications. These complementary analyses allowed the identification of the limitations of our data.
Previous systematic reviews with meta-analysis explored the effects of different antihyperglycemic medica-
tions on mortality or cardiovascular events. Two recent network meta-analysis showed contradictory results: 
one failed to identify evident superiority of any drug class, and the other found that SGLT2i and GLP-1RAs were 
associated with reduced risk of cardiovascular events and  mortality31,32. We believe these results reinforce the 
importance of the hypothesis explored in our systematic review. Individually, several medication classes were 
assessed for benefit or harm in systematic reviews of RCTs and also failed to show a consistent effect on mortal-
ity and cardiovascular  events33–36. Our review broadens these findings and explored the relationship between 
metabolic profile and mechanism of action of these medications and mortality. In the stratified meta-analyses, our 
findings suggest that the metabolic effects of medications must be considered in treatment selection of patients 
with type 2 diabetes. Also, these results agree with current guidelines, that recommend considering other factors 
besides the simple glycemic effects of antihyperglycemic  agents15.
This is the first systematic review exploring this topic, but some primary studies evaluated this research 
question recently. An observational study from a Swedish database showed that glycated hemoglobin, systolic 
blood pressure, and body mass index are all important risk factors for all-cause mortality in patients with type 
2  diabetes37. Individual data from large RCTs also indicate the same pattern. An additional analysis of Look 
AHEAD indicates that patients in the category of greatest weight loss in the first year had decreased risk of cardio-
vascular death and non-fatal cardiovascular events independent from the arm they were originally  randomized38. 
This Look AHEAD analysis, which corroborates our findings, reinforces that diabetes treatments must focus on 
other targets (such as avoidance of hypoglycemia, lower weight gain, and lower blood pressure) in addition to 
glycemic control. Data from EMPA-REG OUTCOME trial suggest that plasma volume contraction may be the 
main determinant of benefits from empagliflozin  treatment39. However, glycemic control, systolic blood pres-
sure, and body weight were also associated with a lower risk of cardiovascular  death39. These studies reinforce 
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the reliability of our findings. Further analyses of primary data from RCTs (individually or through individual 
patient data meta-analysis) could also provide valuable  information17,40.
From a mechanistic point of view, our results are biologically plausible, as better glycemic control, less severe 
hypoglycemic events, lower weight and blood pressure were all associated with better outcomes in subjects with 
type 2 diabetes in observational or interventional  studies1–3. However, this systematic review does not determine 
if: (a) the factors are predictors of a beneficial effect of these medications or; (b) there is a mechanistic relation-
ship between favorable overall medication profile and mortality and cardiovascular events. As we observed small 
changes in the metabolic factors, it seems more likely that there is association rather than causation. That is, 
small changes on intermediate outcomes (glycemic control, severe hypoglycemia risk, body weight, and blood 
pressure) are not expected to be the determinants of reduced mortality risk. We also could not explore the effects 
of medications on cholesterol, as reporting was available only in a few studies.
This study has some limitations inherent to the design used. We aimed to explore the new hypothesis that 
other factors along with mechanism of action of each antihyperglycemic agent might explain the variability on 
its clinical effects. Cochrane Handbook states that subgroup analyses are  observational17, so our findings must 
be considered indirect. They are susceptible to bias, such as confounding. Our results represent an association 
between the study variables and outcomes; so they may not represent causation. Associations between metabolic 
factors, mechanism of action, and outcomes must be confirmed, as most of the meta-regressions did not explain 
the heterogeneity within study results. However, we cannot assume the lack of association between studied fac-
tors and outcomes only based on meta-regression results as “one should never use a nonsignificant finding to 
conclude that the true means in subgroups are the same, or that a covariate is not related to effect size”23. Also, 
as this meta-analysis deals with study-level characteristics, only summarized effects of each study are evaluated 
and relevant association between factors and outcomes may be  missed17. In other words, the link between “bet-
ter metabolic profile” of antihyperglycemic medications and reduced mortality must be further explored and 
studied, ideally with meta-analysis from individual patient  data17,40.
Another issue of this review is the combination of different classes of medications. This problem may be 
considered the main limitation as there is unquestionable clinical heterogeneity in this approach. However, we 
explored this limitation by considering the mechanisms of action of medication in our analyses. Also, this limita-
tion is inherent to addressing the hypothesis that determinants other than the mechanism of action of antihyper-
glycemic agents may mediate the clinical effects of antihyperglycemic agents. The use of different comparators 
is a similar problem. We tried to partially control this limitation by using the differences between study arms 
rather than using the absolute values. Network meta-analysis might deal with the problem of different compara-
tors. However, it does not allow the evaluation of co-factors and we would not be able to explore our hypothesis.
Conclusion
Antihyperglycemic medications that lead to better overall metabolic profile were associated with decreased 
all-cause and cardiovascular mortality in patients with type 2 diabetes. Our results were based on indirect com-
parisons of study-level information and were not confirmed in meta-regression analyses, so this topic must be 
further studied. Although this data must be considered preliminary, it is relevant to patient and clinicians in the 
choice of antihyperglycemic treatment in type 2 diabetes.
Data availability
All relevant data are within the paper and the supplementary material.
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